High-end technology can cut cost in clinical trials

Hyderabad: The breakthrough innovation, data and digital technology are the key priorities to lead innovation in Life Sciences sector in India. “In breakthrough innovation, the main focus should be on high-end transformative innovation including personalised medicine” said, Dr Shreeram Aradhya, chief medical officer of Novartis Pharma, during the keynote address at the BioAsia conclave.

Terming personalised medicine as not a business risk, he said, “Modified human cells can be used as drugs. They can be modified in lab and can infuse them back into cells.”

Due to the advancement in technology, there is increasing awareness in preventive medicine. Furthermore, real world data increasingly recognised as enabler of research and development and the next generation of platform is Data Science.

He said “Artificial intelligence and Machine learning are allowing to progress in Life Sciences sector in a better way. Technology is helping cut costs in the clinical trails”

Preventive medicine is inculcated using real-time monitoring with devices like patches, watches/bands, contact lenses, subcutaneous senors and integrated models. With digital therapies, drugs are being delivered in an intelligent way using assistance tools, apps, virtual reality, games and behavior change.

Speaking about a development on enhancing outcomes in heart failure, Mr Shreeram said, “Enhancing outcomes in a heart failure are recorded using a wifi-enabled device instead of frequent visits to hospitals.”